Business
Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London
Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), announced today the presentation of its five year extended pooled analysis including data from the 17-HMedIdeS-14 study, an international long-term follow-up study of patients who have received a kidney transplant following desensitization with imlifidase, at the 2025 International Transplant Congress of the European Society for Organ Transplantation (ESOT), taking place in London, June 29 – July 2.
About this update from Hansa Biopharma Ab
[{"type":"text","content":"LUND, Sweden, June 30, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), announced today the presentation of its five year extended pooled analysis including data from the 17-HMedIdeS-14 study, an international long-term follow-up study of patients who have received a kidney transplant following desensitization with imlifidase, at the 2025 International Transplant Congress of the European Society for Organ Transplantation (ESOT), taking place in London, June 29 – July 2.","length":510,"tagName":"p"},{"type":"text","content":"Massimo Mangiola, PhD, NYU Langone Transplant Institute, will present the outcomes of the extended pooled analysis including data from the 17-HMedIdeS-14 study, presented at the American Transplant Congress (ATC) 2024, and published as a letter to the editor in the American Journal of Transplantation.1","length":303,"tagName":"p"},{"type":"text","content":"The extended pooled analysis, including data from the 17-HMedIdeS-14 study, showed sustained positive outcomes out to five years of highly sensitized patients who received an imlifidase-enabled kidney transplant. After five years, the patient survival rate was 90% (reflecting three deaths occurring between six months and one year) and graft survival (death censored) was 82%, in line with outcomes seen at three-years.2 At five years, mean estimated glomerular filtration rate (eGFR) or kidney function was 50 mL/min/m2 in the imlifidase treated patients.","length":557,"tagName":"p"},{"type":"text","content":"eGFR is a measure of how well the kidneys are working in the body – higher eGFR indicates better kidney function.3 For many kidney transplant recipients three years post-transplant the mean eGFR is anywhere between 40-60 ml/min per 1.73 m2 with continued decline of eGFR function at five years post-transplant.4","length":311,"tagName":"p"},{"type":"text","content":"Hitto Kaufmann, Chief R&D Officer, Hansa Biopharma said, "We are very pleased to see that the 17-HMedIdeS-14 extended pooled analysis data continue to excite the clinical community. This study demonstrated for the first time that HLA-incompatible transplantation following desensitization with imlifidase is a viable option for patients who need it, with long term benefit comparable to standard kidney transplants, providing a life changing alternative to...